167 related articles for article (PubMed ID: 1428723)
1. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative.
Pierré A; Dunn TA; Kraus-Berthier L; Léonce S; Saint-Dizier D; Régnier G; Dhainaut A; Berlion M; Bizzari JP; Atassi G
Invest New Drugs; 1992 Aug; 10(3):137-48. PubMed ID: 1428723
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
[TBL] [Abstract][Full Text] [Related]
3. In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model.
Cros S; Guilbaud N; Berlion M; Dunn T; Regnier G; Dhainaut A; Atassi G; Bizzari JP
Cancer Chemother Pharmacol; 1992; 30(6):491-4. PubMed ID: 1394807
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W; Fukazawa N; Nakanishi O; Baba M; Suzuki T; Yano O; Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):271-7. PubMed ID: 7828268
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
6. [In vitro characterization of S9788, a new modulator of multidrug resistance].
Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
[TBL] [Abstract][Full Text] [Related]
7. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.
Sato W; Fukazawa N; Suzuki T; Yusa K; Tsuruo T
Cancer Res; 1991 May; 51(9):2420-4. PubMed ID: 1673087
[TBL] [Abstract][Full Text] [Related]
8. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Mayer LD; Lim KT; Hartley D
J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
[TBL] [Abstract][Full Text] [Related]
9. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.
Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Jun; 43(6):2905-10. PubMed ID: 6850602
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by an immunosuppressive agent FK-506.
Naito M; Oh-hara T; Yamazaki A; Danki T; Tsuruo T
Cancer Chemother Pharmacol; 1992; 29(3):195-200. PubMed ID: 1370765
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
[TBL] [Abstract][Full Text] [Related]
12. Circumvention of multidrug resistance in P388 murine leukemia cells by a novel inhibitor of cyclic AMP-dependent protein kinase, H-87.
Miyamoto K; Wakusawa S; Nakamura S; Koshiura R; Otsuka K; Naito K; Hagiwara M; Hidaka H
Cancer Lett; 1990 May; 51(1):37-42. PubMed ID: 2337896
[TBL] [Abstract][Full Text] [Related]
13. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.
Wilkoff LJ; Dulmadge DA; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1989; 23(3):145-50. PubMed ID: 2924372
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of quinidine effect on the antitumor activity of adriamycin and mitoxantrone in adriamycin-sensitive and -resistant P388 leukemia cells.
Parekh H; Chitnis M
Sel Cancer Ther; 1990; 6(2):93-102. PubMed ID: 2367755
[TBL] [Abstract][Full Text] [Related]
15. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.
Tsuruo T; Iida H; Yamashiro M; Tsukagoshi S; Sakurai Y
Biochem Pharmacol; 1982 Oct; 31(19):3138-40. PubMed ID: 7150340
[TBL] [Abstract][Full Text] [Related]
17. New triazine derivatives as potent modulators of multidrug resistance.
Dhainaut A; Régnier G; Atassi G; Pierré A; Léonce S; Kraus-Berthier L; Prost JF
J Med Chem; 1992 Jun; 35(13):2481-96. PubMed ID: 1352353
[TBL] [Abstract][Full Text] [Related]
18. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide.
Nakashima E; Matsushita R; Negishi H; Nomura M; Harada S; Yamamoto H; Miyamoto K; Ichimura F
J Pharm Sci; 1995 Oct; 84(10):1205-9. PubMed ID: 8801335
[TBL] [Abstract][Full Text] [Related]
19. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.
Kurosawa K; Takahashi K; Tsuda E; Tomida A; Tsuruo T
Jpn J Cancer Res; 2001 Nov; 92(11):1235-41. PubMed ID: 11714449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
